EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 590 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Why haven’t we cured cancer? – That Cancer Conversation June 14, 2022 Engaging People with Low-Grade Glioma in Cancer Research August 24, 2023 UK sunburn risk: Third of adults more likely to protect their... August 2, 2021 FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... July 6, 2023 Load more HOT NEWS Daratumumab Plus Bortezomib and Dexamethasone Regimen Significantly Prolongs OS in Patients... Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe.... FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Paediatric Patients...
